ClinicalTrials.gg
CompletedNCT05278416HOPE-CPUpdated Jan 22, 2026

Regular Home Use of Dual-light Photodynamic Therapy in the Management of Chronic Periodontitis

An interventional study of Lumoral treatment -device and Lumorinse tablets in Periodontitis, sponsored by Koite Health Oy. Completed at 1 site in Finland. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Koite Health Oy · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The study is a single site, randomized clinical trial designed to determine the efficacy of the Lumoral treatment in periodontitis patients.

Read the detailed description

Lumoral treatment is a CE-marked medical device developed to provide a potent, targeted antibacterial action on dental plaque in a home environment. The device mechanism of action is antibacterial photodynamic therapy. The device is used by swishing a mouth rinse, strongly adhering to dental plaque. The plaque-adhered photoactive mouth rinse can be activated by a simple use light applicator. The antibacterial efficacy far exceeds chlorhexidine, without side effects in long-term use. Preliminary results have shown a promising anti-inflammatory response in addition to plaque reduction.

This early-stage study is designed to determine the efficacy of the Lumoral method in periodontitis patients. Improved supragingival plaque control can help to also sustain subgingival plaque management in the long term. In addition, the device might have a photobiomodulation effect on periodontal tissues.

02

Conditions studied

  • Periodontitis

Browse trials for

Keywords

  • Lumoral
  • Lumorinse
  • Periodontitis
  • Anti-bacterial photodynamic therapy
  • aPDT
  • Plaque
  • aMMP-8
03

In context

Periodontitis

1,242 studies on the registry are indexed under Periodontitis; 304 are open to participants now.

This study's enrollment of 202 is above the median of 44 across 850 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Koite Health Oy is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Periodontal disease stage I-III, according to criteria the American Academy of Periodontology (AAP) with at least 2 mm interdental CAL in the site of greatest loss
  • Age of 18-85 years
  • Presence of > 20 teeth
  • Agreement to participate in the study and to sign a written consent form

Exclusion criteria

Exclusion Criteria:

  • Untreated/uncontrollable diabetes mellitus (DM) with >7%, and HbA1c > 8 if insulin treated DM
  • Any systemic disease (e.g., wound healing dysfunctions) that could alter the progression of periodontal disease
  • Use of medicine that would affect the periodontal tissue within the last 6 months (antibiotics, anti-inflammatories, anticonvulsants, , or calcium channel blockers, including doxycycline, bisphosphonates and chlorhexidine)
  • Periodontal treatment during the previous 3 months
  • Allergic to the photosensitizer
  • Presence of major physical limitation or restriction that prohibit the hygiene procedures used in the study protocol
  • Removable major prosthesis or major orthodontic appliance
  • Active smoking, or habitual use of smokeless tobacco products
  • Pregnancy or lactation
  • A need for a hopeless teeth extraction, or open cavities in need for immediate endodontic treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
202 participants (actual)

Study arms

  • Active comparator
    Lumoral treatment -device and Lumorinse tablets

    Subjects will receive detailed instructions for the use of Lumoral treatment -device and Lumorinse tablets. Subjects will be instructed to use the Lumoral treatment -device and follow the protocol once a day.

    Device: Lumoral treatment -device and Lumorinse tablets

  • No intervention
    Standard of Care

    Subjects will receive oral hygiene instructions for the sonic toothbrushing and the use of interdental cleaning devices. They will not receive an additional intervention.

Interventions

  • DeviceLumoral treatment -device and Lumorinse tablets

    Subjects will use Lumoral treatment -device and Lumorinse tablets daily as per protocol.

06

What researchers measure

Primary outcomes

  1. Bleeding on Probing (BOP)

    Clinical change concerning bleeding on probing change. A full-mouth assessment at six sites per tooth (mesiobuccal, buccal, distobuccal, mesiolingual, lingual, distolingual). Gingival bleeding is considered as positive if bleeding occurs within 15 seconds after gentle probing with a probe at the sulcus. Dichotomous scoring to each site of the tooth as bleeding "1 present" and "0 absent". BOP is reported as the percentage (%) of sites with positive findings. Calculation formula: number of bleeding sites/ 6 times number of teeth.

    Time frame: 6 months

Secondary outcomes

  1. Clinical Attachment Level (CAL)

    Observation of clinical attachment level: A full-mouth assessment, measured at six sites per tooth. Assessed as the distance from the cementoenamel junction (CEJ) to the bottom of the periodontal pocket (mm). To calculate CAL, two measurements are needed: distance from the gingival margin to the CEJ and PPD; in recession: PPD + gingival margin to the CEJ; in tissue overgrowth: PPD - gingival margin to the CEJ.

    Time frame: 6 months

  2. Periodontal Pocket Depth (PPD)

    A full-mouth assessment, measured at six sites per tooth. Assessed from the base of the pocket to the gingival margin (mm)

    Time frame: 6 months

  3. Device-related adverse events

    Absence of device-related serious adverse events or any patterns of device-related adverse events graded as moderate

    Time frame: 6 months

  4. Inflammation marker aMMP-8 measurement

    Change in aMMP8-measurement reflecting the reduction in periodontitis grade. The oral rinse fluid sample collection and the aMMP-8 marker analysis will be performed using Periosafe test (Dentognostics GmbH) according to the manufacturer's instructions.

    Time frame: 6 months

  5. Visual Plaque Index (VPI)

    Assessment of six index teeth, measured at four sites per tooth Dichotomous scoring to each site of the tooth as plaque "1 present" and "0 absent" VPI reported as the percentage (%) of sites with plaque Calculation formula: number of sites with plaque/ 4 times number of teeth.

    Time frame: 6 months

  6. OHIP-14

    Patient related objectives: Oral-related quality of life measurement (OHIP-14) questionnaire.

    Time frame: 6 months

  7. Patient-related objective: PCS questionnaire

    Measurements of internal motivation to dental hygiene by Perceived Competence Scale (PCS) questionnaire.

    Time frame: 6 months

  8. Patient-related objective: OSCA questionnaire

    Measurements of internal motivation to dental hygiene by Oral Self-Care Assessment (OSCA) questionnaire

    Time frame: 6 months

07

Study locations

1 site
  • Metropolia University of applied sciences
    Helsinki, Finland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Apr 2025, 38 months.

Of 498 interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's 38 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2022
First posted
Mar 14, 2022
StartActual
Feb 8, 2022
Primary completionActual
Apr 14, 2025
CompletionActual
Apr 29, 2025
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05278416
Lead sponsor
Koite Health Oy
Collaborators
University of Helsinki, Metropolia University of Applied Sciences
Responsible party
Sponsor
First posted
Mar 14, 2022
Start date
Feb 8, 2022
Primary completion
Apr 14, 2025
Completion
Apr 29, 2025
Last update
Jan 22, 2026

Study contacts

Timo Sorsa, Professor
principal investigator · Univeristy of Helsinki
Tommi Pätilä, Docent
study director · Koite Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion